secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001104659-25-074719
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q2 net loss $34.8M; icotrokinra NDA filed, rusfertide NDA on track
------------------------------------------------------------------------------

- Net loss $34.8M ($0.55/share) vs $30.6M in Q2 2024; license revenue $5.5M from Takeda.
- Cash $673M as of June 30, sufficient for runway through at least end 2028.
- NDA for icotrokinra (moderate-to-severe plaque psoriasis) submitted to FDA in July.
- Rusfertide NDA for polycythemia vera expected Q4 2025; Phase 3 VERIFY data presented at ASCO.
- Pipeline: PN-477 oral/subcutaneous triple agonist for obesity selected; PN-881 IL-17 antagonist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465925074719/0001104659-25-074719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465925074719/tm2522652d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-074719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer